We have shown improved overall survival and reduced metabolic changes associated with pancreatic cancer cachexia in animals treated with TGF-β inhibitor and suggest a promising role for TGF-β blockade as a therapeutic strategy in this otherwise terminal process. Here, TGFB1 is linked to familial pancreatic carcinoma.